Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22567
Title: Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.
Authors: Leimgruber, Antoine;Hickson, Kevin;Lee, Sze Ting;Gan, Hui K;Cher, Lawrence M;Sachinidis, John I;O'Keefe, Graeme J;Scott, Andrew M
Affiliation: Medical Physics and Radiation Safety, South Australia Medical Imaging, Adelaide, Australia
Service of Medical Imaging, Hospital Riviera Chablais, Rennaz, Switzerland
School of Cancer Medicine, La Trobe University, Melbourne, Australia
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Service of Medical Imaging, Hospital Riviera Chablais, Rennaz, Switzerland..
Issue Date: 5-Feb-2020
EDate: 2020
Citation: European journal of nuclear medicine and molecular imaging 2020; online first: 5 February
Abstract: Tumor hypoxia is a centerpiece of disease progression mechanisms such as neoangiogenesis or aggressive hypoxia-resistant malignant cells selection that impacts on radiotherapy strategies. Early identification of regions at risk for recurrence and prognostic-based classification of patients is a necessity to devise tailored therapeutic strategies. We developed an image-based algorithm to spatially map areas of aerobic and anaerobic glycolysis (Glyoxia). 18F-FDG and 18F-FMISO PET studies were used in the algorithm to produce DICOM-co-registered representations and maximum intensity projections combined with quantitative analysis of hypoxic volume (HV), hypoxic glycolytic volume (HGV), and anaerobic glycolytic volume (AGV) with CT/MRI co-registration. This was applied to a prospective clinical trial of 10 glioblastoma patients with post-operative, pre-radiotherapy, and early post-radiotherapy 18F-FDG and 18F-FMISO PET and MRI studies. In the 10 glioblastoma patients (5M:5F; age range 51-69 years), 14/18 18F-FMISO PET studies showed detectable hypoxia. Seven patients survived to complete post-radiotherapy studies. The patient with the longest overall survival showed non-detectable hypoxia in both pre-radiotherapy and post-radiotherapy 18F-FMISO PET. The three patients with increased HV, HGV, and AGV volumes after radiotherapy showed 2.8 months mean progression-free interval vs. 5.9 months for the other 4 patients. These parameters correlated at that time point with progression-free interval. Parameters combining hypoxia and glycolytic information (i.e., HGV and AGV) showed more prominent variation than hypoxia-based information alone (HV). Glyoxia-generated images were consistent with disease relapse topology; in particular, one patient had distant relapse anticipated by HV, HGV, and AGV maps. Spatial mapping of aerobic and anaerobic glycolysis allows unique information on tumor metabolism and hypoxia to be evaluated with PET, providing a greater understanding of tumor biology and potential response to therapy.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22567
DOI: 10.1007/s00259-020-04706-0
ORCID: 0000-0002-6656-295X
0000-0001-8641-456X
PubMed URL: 32025750
Type: Journal Article
Subjects: 18F-FDG
18F-FMISO PET
Glioblastoma
Glyoxia
Hypoxia
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.